Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Grape King Bio Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This study was designed as randomized double blind placebo study to investigate the efficacy of Erinacine A-enriched Hericium erinaceus mycelia for improvement of recognition, vision, and functional MRI alterations.
Patients were recruited with diagnosis of mild or medium dementia, according to criteria by NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association) as probable or possible Alzheimer's disease. Upon signature of informed consent, they were subject to: (1) Cognitive assessments, including Mini-Mental State Examination(MMSE), Neuropsychiatric Inventory (NPI), Cognitive Abilities Screening Instrument (CASI), and Instrumental Activities of Daily Living (IADL) on weeks 0, 12, 24, and 49, (2) Blood Markers Tests, including DHEAS, Alpha 1-antichymotrypsin, Superoxide Dismutase, and Homocysteine, Apolipoprotein E, Hemoglobin, Calcium, Albumin, and Amyloid Beta on weeks 0, 24, and 49, (3) fMRI Assessments for Super-resolution Track Density Imaging (TDI), and Blood Oxygenation Level-Dependent (BOLD) Signal Mapping, on weeks 0 and 49, (4) Vision Assessments, including Visual Acuity (VA) and Contrast Sensitivity (CS), on weeks 0, 24, and 49. Mann-Whitney U test and Wilcoxon tests were applied to examine the data before and after dietary intake of Erinacine A-enriched Hericium Erinaceus Mycelia after 49 weeks.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental | Experimental | Erinacine A-enriched Hericium Erinaceus Mycelia dietary supplement from week 0 to week 49. |
|
| Placebo | Placebo Comparator | Placebo dietary supplement from week 0 to week 49. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Erinacine A-enriched Hericium Erinaceus Mycelia | Dietary Supplement |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Mini-Mental State Examination(MMSE) | Assess changes of Mini-Mental State Examination(MMSE) on weeks 0, 12, 24, and 49. | weeks 0,12, 24, and 49 |
| Neuropsychiatric Inventory (NPI) | Assess changes of Neuropsychiatric Inventory (NPI) on weeks 0, 12, 24, and 49. | weeks 0,12, 24, and 49 |
| Cognitive Abilities Screening Instrument (CASI) | Assess changes of Cognitive Abilities Screening Instrument (CASI) on weeks 0, 12, 24, and 49. | weeks 0,12, 24, and 49 |
| Instrumental Activities of Daily Living (IADL) | Assess changes of Instrumental Activities of Daily Living (IADL) on weeks 0, 12, 24, and 49. | weeks 0,12, 24, and 49 |
| Dehydroepiandrosterone sulfate (DHEAS) | Assess changes of DHEAS on weeks 0, 24, and 49. | weeks 0, 24, and 49 |
| Alpha 1-antichymotrypsin | Assess changes of Alpha 1-antichymotrypsinon weeks 0, 24, and 49. | weeks 0, 24, and 49 |
| Superoxide Dismutase | Assess changes of Superoxide Dismutase on weeks 0, 24, and 49. | weeks 0, 24, and 49 |
| Homocysteine |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Pei-Cheng Lin, PhD | Chung Shan Medical University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chung Shan Medical University Hospital | Taichung | 40201 | Taiwan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32581767 | Derived | Li IC, Chang HH, Lin CH, Chen WP, Lu TH, Lee LY, Chen YW, Chen YP, Chen CC, Lin DP. Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. Front Aging Neurosci. 2020 Jun 3;12:155. doi: 10.3389/fnagi.2020.00155. eCollection 2020. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Randomized Double Blinded placebo study
Not provided
Not provided
to be completed
| Dietary Supplement |
Placebo supplement was given to the participants. |
|
Assess changes of Homocysteine on weeks 0, 24, and 49.
| weeks 0, 24, and 49 |
| Apolipoprotein E | Assess changes of Apolipoprotein E on weeks 0, 24, and 49. | weeks 0, 24, and 49 |
| Hemoglobin | Assess changes of Hemoglobin on weeks 0, 24, and 49. | weeks 0, 24, and 49 |
| Calcium | Assess changes of Calcium on weeks 0, 24, and 49. | weeks 0, 24, and 49 |
| Albumin | Assess changes of Albumin on weeks 0, 24, and 49. | weeks 0, 24, and 49 |
| Amyloid Beta | Assess changes of Amyloid Beta on weeks 0, 24, and 49. | weeks 0, 24, and 49 |
| fMRI-Super-resolution Track Density Imaging (TDI) | Assess changes of Super-resolution Track Density Imaging (TDI) on weeks 0 and 49. | weeks 0 and 49 |
| fMRI-Blood Oxygenation Level-Dependent (BOLD) Signal Mapping | Assess changes of Blood Oxygenation Level-Dependent (BOLD) Signal Mapping, on weeks 0 and 49. | weeks 0 and 49 |
| Vision Assessments-Visual Acuity (VA) | Assess changes of Visual Acuity (VA) on weeks 0, 24, and 49. | weeks 0, 24, and 49 |
| Vision Assessments-Contrast Sensitivity (CS) | Assess changes of Contrast Sensitivity (CS) on weeks 0, 24, and 49. | weeks 0, 24, and 49 |
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided